167412-23-9 Usage
Uses
Used in Medicinal Chemistry Research:
N-(3,5-DIFLUOROPHENYL)HYDRAZINECARBOXAMIDE is used as a building block for the synthesis of biologically active compounds, serving as a key component in the development of potential pharmaceuticals.
Used in Pharmaceutical Development:
N-(3,5-DIFLUOROPHENYL)HYDRAZINECARBOXAMIDE is used as a precursor in the creation of new drugs, specifically targeting the development of antitumor agents and treatments for certain neurological disorders.
Used in Antitumor Research:
N-(3,5-DIFLUOROPHENYL)HYDRAZINECARBOXAMIDE is used as an antitumor agent, being studied for its potential to combat cancer by interfering with tumor growth and progression mechanisms.
Used in Neurological Disorder Treatment:
N-(3,5-DIFLUOROPHENYL)HYDRAZINECARBOXAMIDE is used in the treatment of certain neurological disorders, leveraging its chemical structure to potentially alleviate symptoms or modify the course of these conditions.
The unique chemical structure of N-(3,5-DIFLUOROPHENYL)HYDRAZINECARBOXAMIDE positions it as an intriguing candidate for ongoing research and development within the medicinal chemistry field, with applications spanning from basic research to clinical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 167412-23-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,7,4,1 and 2 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 167412-23:
(8*1)+(7*6)+(6*7)+(5*4)+(4*1)+(3*2)+(2*2)+(1*3)=129
129 % 10 = 9
So 167412-23-9 is a valid CAS Registry Number.
InChI:InChI=1/C7H7F2N3O/c8-4-1-5(9)3-6(2-4)12(11)7(10)13/h1-3H,11H2,(H2,10,13)
167412-23-9Relevant academic research and scientific papers
Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors
Qi, Baohui,Tao, Haiyan,Wu, Di,Bai, Jinying,Shi, Yandan,Gong, Ping
, p. 596 - 609 (2013/09/02)
Novel quinoline derivatives bearing acyclic semicarbazones were prepared and their chemical structures as well as the relative stereochemistry were confirmed. All the synthesized compounds were evaluated for their c-Met kinase inhibitory activity and their cytotoxicity against the cell lines HT-29, MKN-45, and MDA-MB-231 in vitro. Several potent compounds were further evaluated against A549 cells. Most compounds displayed moderate to excellent activity, and the structure-activity relationship studies identified the most promising compound 35 as a selective c-Met kinase inhibitor (IC50 = 4.3 nM). Compound 35 showed a 3.5- and 18.8-fold increase in cytotoxicity in vitro against HT-29 and A549 cells, respectively, compared to that of foretinib. Poor off-target effects of compound 35 were further confirmed by the antiproliferative activity against the c-Met inhibition less sensitive MDA-MB-231 cell line (IC50 = 0.77 μM). Copyright
